LFCR
NASDAQLifecore Biomedical Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News25/Ratings6
News · 26 weeks39+38%
2025-12-142026-06-07
Mix2990d
- Other12(41%)
- Insider9(31%)
- SEC Filings5(17%)
- Earnings2(7%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Obus Nelson was granted 25,907 shares, increasing direct ownership by 19% to 164,100 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- INSIDERDirector Houde Lovas Katrina was granted 25,907 shares, increasing direct ownership by 24% to 135,319 units (SEC Form 4)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical Signs Agreement with New Biopharmaceutical Customer-- Agreement Calls for Tech Transfer in Preparation for Potential Commercial Manufacturing of Injectable Ophthalmic Product -- -- Sixth Addition to Late-Stage Pipeline in Seven Months -- CHASKA, Minn., June 02, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed a manufacturing services agreement with a leading provider of ophthalmic disease management solutions. Under the terms of the agreement, Lifecore will perform process development and technical transfer services in support of anticipated commercial manufacturing upon regulatory
- INSIDERChief Executive Officer Josephs Paul covered exercise/tax liability with 40,413 shares, decreasing direct ownership by 6% to 592,915 units (SEC Form 4) (withholding tax)4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- PRLifecore Biomedical to Participate in William Blair 46th Annual Growth Stock ConferenceCHASKA, Minn., May 21, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate in the William Blair 46th Annual Growth Stock Conference. The conference will take place June 2-4, 2026, in Chicago, IL. Details regarding Lifecore's participation are as follows: William Blair 46th Annual Growth Stock ConferenceDetails: Lifecore management, including Paul Josephs, chief executive officer, and Ryan Lake, chief financial officer, will participate in investor meetings. Conference Dates: June 2-4, 2026Location: Loews Chicago Hotel,
- PRLifecore Biomedical to Participate at CDMO Live EuropeCHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at CDMO Live Europe. The conference will take place May 19-21, 2026, in Rotterdam, Netherlands. Details regarding Lifecore's participation are as follows: CDMO Live EuropeDetails: Ryan Swanson, Ph.D., Lifecore's director of manufacturing science and technology, will participate in a panel discussion, and the company will host meetings with prospective customers to discuss process development and manufacturing services for injectables programs.Pan
- SECSEC Form 10-Q filed by Lifecore Biomedical Inc.10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- SECLifecore Biomedical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Biomedical Reports Financial Results for the First Quarter Ended March 31, 2026, and Provides Corporate Update-- Reaffirms 2026 Guidance -- -- Signed Three New Commercial Site Transfer Programs in First Quarter 2026 -- -- Cost Containment Initiatives Continue to Drive Down Expenses -- Conference Call Today at 8:00am ET CHASKA, Minn., May 06, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced results for the first quarter ended March 31, 2026. CEO Commentary "During the first quarter, Lifecore continued to successfully execute the three pillars of its growth strategy – maximizing our existing commercial business, advancing our development pipeline toward com
- PRLifecore Biomedical to Report Financial Results for the First Quarter Ended March 31, 2026, on May 6, 2026CHASKA, Minn., April 29, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it will report financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, before the market opens. At 8:00 a.m. Eastern Time that day, members of Lifecore's senior management team will host a webcast to discuss the results. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore's website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an arch
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lifecore Biomedical Inc.SCHEDULE 13G/A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Subject)
- SECSEC Form DEF 14A filed by Lifecore Biomedical Inc.DEF 14A - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)
- PRLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CHASKA, Minn., April 22, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on April 20, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 5,000 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was granted
- INSIDERSEC Form 4 filed by Salus Thomas D.4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)
- PRLifecore Biomedical to Participate at 12th Annual American Biomanufacturing SummitCHASKA, Minn., April 08, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that the company will participate at the 12th Annual American Biomanufacturing Summit. The conference will take place April 14 - 15, 2026, in San Francisco, CA. Details regarding Lifecore's participation are as follows: 12th Annual American Biomanufacturing SummitDetails: Lifecore team will be present to discuss process development and manufacturing services for injectables programs.Booth number: 41 Conference Dates: April 14 - 15, 2026Location: Hyatt Regency San Francisco Airp
- PRLifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore") a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit ("RSU") award with respect to 18,500 shares of its common stock under Lifecore's Equity Inducement Plan, as amended (the "Inducement Plan") to a newly hired employee of Lifecore. The RSU award was granted pursuant to the offer letter between Lifecore and the employee, and as a material inducement to the employee joining Lifecore. The RSU award was approved by Lifecore's compensation committee and was grante
- PRLifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore's High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed two CDMO manufacturing service agreements with an existing
- PRLifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ:LFCR) ("Lifecore"), a fully integrated injectables contract development and manufacturing organization ("CDMO"), today announced that it has signed a CDMO manufacturing services agreement with a new aesthetics customer for an established, market-approved product. Under the terms of the agreement, Lifecore will perform technical transfer services inclu
- ANALYSTLifecore Biomedical upgraded by Barrington Research with a new price targetBarrington Research upgraded Lifecore Biomedical from Mkt Perform to Outperform and set a new price target of $5.50
LFCR FAQ
5 questionsWhere does LFCR stock trade?
Lifecore Biomedical Inc. (LFCR) is listed on NASDAQ.What sector and industry is LFCR in?
Lifecore Biomedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LFCR?
Lifecore Biomedical Inc. has had 6 recent analyst actions on file. The most recent action was from Barrington Research: Outperform with a $550.00 price target on 2026-03-17. Recent price targets range from $200.00 to $800.00.What companies are similar to LFCR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LFCR side-by-side with any of them on Quantisnow.How can I track LFCR on Quantisnow?
Quantisnow aggregates Lifecore Biomedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LFCR to receive live email and push alerts on every new disclosure.